Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that an ...

CDR-Life today announced the expansion of its product portfolio with the nomination of CDR111 as a new clinical candidate for autoimmune diseases along with upcoming posters highlighting the company's ...